Does COVID-19 predispose patients to type 1 diabetes mellitus?

Basit Öğe Kaydı
dc.authoridatik-altınok, yasemin/0000-0001-5851-1012
dc.authoridKirkgoz, Tarik/0000-0003-3450-9780
dc.authorscopusid57216201215
dc.authorscopusid57418123200
dc.authorscopusid57202774693
dc.authorscopusid57222055267
dc.authorscopusid56203491900
dc.authorscopusid15060967600
dc.authorscopusid7006145827
dc.authorwosidata, aysun/GSD-7045-2022
dc.authorwosidatik-altınok, yasemin/A-5858-2019
dc.contributor.authorAta, Aysun
dc.contributor.authorJalilova, Arzu
dc.contributor.authorKirkgoz, Tarik
dc.contributor.authorIsiklar, Hafize
dc.contributor.authorDemir, Gunay
dc.contributor.authorAltinok, Yasemin Atik
dc.contributor.authorOzkan, Behzat
dc.date.accessioned2023-01-12T20:10:43Z
dc.date.available2023-01-12T20:10:43Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractThe novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo-18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61(52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.en_US
dc.identifier.doi10.1297/cpe.31.2021-0050
dc.identifier.endpage37en_US
dc.identifier.issn0918-5739
dc.identifier.issn1347-7358
dc.identifier.issue1en_US
dc.identifier.pmid35002066en_US
dc.identifier.scopus2-s2.0-85126069603en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage33en_US
dc.identifier.urihttps://doi.org/10.1297/cpe.31.2021-0050
dc.identifier.urihttps://hdl.handle.net/11454/77898
dc.identifier.volume31en_US
dc.identifier.wosWOS:000791401800005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJapanese Soc Pediatric Endocrinologyen_US
dc.relation.ispartofClinical Pediatric Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectdiabetes mellitusen_US
dc.subjecttype-1en_US
dc.subjectchildrenen_US
dc.subjectInfectionsen_US
dc.subjectAutoimmunityen_US
dc.subjectCoronavirusen_US
dc.subjectMortalityen_US
dc.subjectChildrenen_US
dc.titleDoes COVID-19 predispose patients to type 1 diabetes mellitus?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu